A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2017
At a glance
- Drugs DCC 2618 (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms invictus
- Sponsors Deciphera Pharmaceuticals
- 21 Nov 2017 Status changed from planning to not yet recruiting.
- 14 Nov 2017 According to a Deciphera Pharmaceuticals media release, company is planning to initiate the study in first half of 2018.
- 09 Jun 2017 New trial record